October 21, 2024 Botox Expands Below the Face: FDA Nod FDA approved onabotulinumtoxinA for platysma bands; 65% of patients reported satisfaction in clinical trials. Conexiant
October 14, 2024 p300 KAT Inhibitors Offer Potential Approach for Inflammatory and Autoimmune Conditions Conexiant
September 24, 2024 Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma: Final Results of the COMBI-AD Trial The ASCO Post
June 24, 2024 Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma The ASCO Post
August 06, 2024 Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma: Final Results of the COMBI-AD Trial The ASCO Post
May 27, 2021 Study Finds Adjuvant Immunotherapy of Benefit to Patients With Stage IIB/C Melanoma The ASCO Post